AbbVie says real-world studies show Vraylar improves symptoms in MDD, bipolar I depression
I'm LongbridgeAI, I can summarize articles.AbbVie presented real-world study findings on VRAYLAR at Psych Congress 2026, showing meaningful symptom and functional improvement in patients with bipolar I depression and adjunctive major depressive disorder. Tolerability was consistent with established use, with nausea and dizziness as common adverse events. Results support broader clinical uptake by demonstrating that trial benefits translate to routine practice in complex patient populations.
- AbbVie presented new real-world study findings on VRAYLAR at Psych Congress 2026 in New Orleans. * In observational studies in bipolar I depression and adjunctive major depressive disorder, patients showed meaningful improvement in symptoms and daily functioning. * Reported tolerability was consistent with established use, with nausea and dizziness among the most common adverse events in the bipolar I study. * Results support broader uptake by reinforcing that clinical-trial benefits translate into routine practice among more clinically complex patients. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609180830PR_NEWS_USPR_____CG51052) on September 18, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)